Chymase Angiotensin-(1-12) Axis In Hypertensive Disease
Determine the presence of the human sequence of Angiotensin-(1-12) in plasma of ten untreated hypertensive subjects and after 4 week with Lisinopril 40 mg every day. Determine the blood pressure reduction with Lisinopril 40mg.
Conditions:
🦠 Hypertension
🗓️ Study Start (Actual) 15 November 2022
🗓️ Primary Completion (Estimated) 31 March 2023
✅ Study Completion (Estimated) 31 March 2023
👥 Enrollment (Estimated) 10
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 Carrollton, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • 1. Capable of reading, comprehending the consent process and providing written informed consent to participate in the study
    • 2. Subject willing to comply with all study visits/procedures and be available for the duration of the study
    • 3. Male or female 40 years of age to 75 years of age
    • 4. Male and female subjects naive to anti-hypertensive medications or receiving no anti-hypertensive medication for at least 6 months prior to visit 1
    • 5. Stage I-II hypertension defined as a baseline mean seated cuff Diastolic blood pressure of equal/over 90 mm Hg and equal/less 109 mm Hg and/or Systolic blood pressure equal/over 140 mm Hg and equal/less 179 mm Hg on visit 1
    • 6. Women may be enrolled if all three of the following criteria are met:
    • Have a negative urine pregnancy test at visit 1, for females of childbearing potential Are not breastfeeding Do not plan to become pregnant during the study And if one of the following three criteria is met Have had a hysterectomy or tubal ligation at least six months prior to signing the informed consent form Have been postmenopausal for at least one year Are of childbearing potential and will practice one of the following methods of birth control though out the study: oral, patch, injectable, or implantable hormone contraception, intrauterine device, diaphragm plus spermicide or female condom plus spermicide. Abstinence, partner's vasectomy are not acceptable methods of contraception

    Exclusion Criteria:

    • -
Ages Eligible for Study: 40 Years to 75 Years (ADULT, OLDER_ADULT)
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 22 November 2022
  • First Submitted that Met QC Criteria 6 December 2022
  • First Posted 9 December 2022

Study Record Updates

  • Last Update Submitted that Met QC Criteria 6 December 2022
  • Last Update Posted 9 December 2022
  • Last Verified December 2022